Thermo Fisher Scientific Inc. $TMO Shares Sold by Associated Banc Corp

Associated Banc Corp cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,447 shares of the medical research company’s stock after selling 968 shares during the quarter. Associated Banc Corp’s holdings in Thermo Fisher Scientific were worth $21,073,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of TMO. Brighton Jones LLC increased its position in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Intrua Financial LLC raised its position in Thermo Fisher Scientific by 11.6% in the first quarter. Intrua Financial LLC now owns 579 shares of the medical research company’s stock valued at $288,000 after purchasing an additional 60 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Thermo Fisher Scientific by 19.6% in the first quarter. Jones Financial Companies Lllp now owns 103,983 shares of the medical research company’s stock worth $51,920,000 after buying an additional 17,068 shares during the period. Finally, Modern Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 7.4% in the first quarter. Modern Wealth Management LLC now owns 6,074 shares of the medical research company’s stock valued at $3,023,000 after buying an additional 420 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $619.14 on Friday. The stock has a market capitalization of $232.62 billion, a price-to-earnings ratio of 35.77, a PEG ratio of 4.07 and a beta of 0.91. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $628.08. The company’s 50-day simple moving average is $581.35 and its 200-day simple moving average is $517.34. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a stock buyback program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of equities analysts have weighed in on TMO shares. Hsbc Global Res upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Monday, December 1st. The Goldman Sachs Group initiated coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 9th. They set a “buy” rating and a $685.00 price target for the company. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Finally, Citigroup raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and increased their price target for the company from $580.00 to $660.00 in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $625.47.

Insider Activity

In related news, COO Michel Lagarde sold 22,046 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the sale, the chief operating officer owned 84,117 shares in the company, valued at $47,404,976.52. This represents a 20.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Frederick M. Lowery sold 6,912 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total value of $4,022,369.28. Following the completion of the transaction, the executive vice president owned 14,367 shares of the company’s stock, valued at approximately $8,360,731.98. The trade was a 32.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 149,271 shares of company stock valued at $86,507,282 over the last quarter. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.